NeoPharm (092730.KQ) Earnings Analysis

NeoPharm (092730.KQ) has no confirmed upcoming earnings date. It has beaten estimates in 1/1 recent quarters (100%). Trailing P/E 10.25.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does 092730.KQ next report earnings?

No confirmed upcoming earnings date is currently scheduled for 092730.KQ. This page updates as the calendar is published.

092730.KQ earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-08551 KRWn/an/an/a
2026-01-27432.19 KRWn/an/an/a
2025-11-07439 KRWn/an/an/a
2025-05-09455.99 KRWn/an/an/a
2025-03-17430.56 KRWn/an/an/a
2024-11-13276.95 KRWn/an/an/a
2024-08-12254.5 KRW233 KRW+9.2%Beat

Beat rate: 1/1 (100%) over reported quarters with consensus data.

092730.KQ valuation and analyst view

Trailing P/E10.25
Trailing EPS1,828.68 KRW
Price / book1.60
Dividend yield3.12%
Market cap291.40B

Limited or no published sell-side analyst coverage for this symbol.

Related research pages

Frequently asked questions

When is NeoPharm (092730.KQ)'s next earnings date?

No confirmed upcoming earnings date is currently scheduled for 092730.KQ. This page updates as the calendar is published.

Did 092730.KQ beat earnings last quarter?

Consensus estimate data was not available for 092730.KQ's 2026-05-08 report.

What is 092730.KQ's earnings track record?

Over the last 1 reported quarters with consensus data, 092730.KQ beat estimates 1 times (100%).

What is 092730.KQ's current P/E ratio and EPS?

092730.KQ trades at a trailing P/E of 10.25 on trailing EPS of 1828.682407037684 KRW.

What do analysts rate 092730.KQ?

092730.KQ has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.